Browse the evidence

The magnitude of the acute satellite cell (SC) response to resistance exercise, specifically the expansion of type I fiber-associated SC between 24 and 72 hours post-exercise, positively correlates with the degree of skeletal muscle hypertrophy achieved following long-term resistance training.

If you want to maximize muscle growth from resistance training, focus on exercises that trigger a strong satellite cell response. This study suggests that the ability of your body to expand the satellite cell pool associated with type I muscle fibers in the 24-72 hours after a workout is a key predictor of how much muscle you will gain over time. This implies that recovery and the cellular environment post-workout are just as important as the workout intensity itself.

The expansion of the satellite cell pool associated with type II muscle fibers following long-term resistance training correlates with the degree of skeletal muscle hypertrophy.

Long-term resistance training leads to an expansion of the satellite cell pool, particularly in type II fibers, which is associated with greater muscle growth. This suggests that consistent training over weeks and months helps build a larger reservoir of stem cells, supporting larger muscle fibers.

Myostatin (MSTN) co-localization with satellite cells decreases acutely following resistance exercise but returns to baseline levels after long-term resistance training, suggesting MSTN regulation occurs at the whole muscle level rather than specifically at the satellite cell level during chronic adaptation.

While acute exercise reduces the presence of the muscle growth inhibitor Myostatin on satellite cells, this effect does not persist after long-term training. This suggests that long-term muscle growth is not driven by chronic MSTN inhibition at the satellite cell level, but rather by other mechanisms like myonuclear addition.

Tirzepatide, a dual agonist of GLP-1 and GIP receptors, achieves significant body weight and glucose control in patients with obesity and type 2 diabetes.

Tirzepatide, which activates both GLP-1 and GIP receptors, is an effective treatment for obesity and type 2 diabetes, leading to significant improvements in body weight and glucose control. It represents a newer class of therapy with promising clinical results.

Short-term time-restricted feeding (8h window) alters the rhythmicity of serum lipids and muscle amino acids without perturbing core clock gene expression in skeletal muscle.

If you practice time-restricted feeding, expect changes in how your body processes fats and amino acids throughout the day, specifically by increasing the 'peaks' of certain metabolic signals in muscle. This happens even if your body's core biological clock genes remain unchanged. Focus on the timing of nutrient availability rather than trying to 'reset' your biology.

Multi-targeting agonists (tirzepatide and peptide 20) that activate GIPR, GLP-1R, and GCGR provide superior metabolic efficacy compared to GLP-1 mono-agonists (like semaglutide) by leveraging distinct structural binding modes and retaining glucagon receptor function.

For individuals managing Type 2 Diabetes or Obesity, newer multi-targeting therapies (like tirzepatide) that activate multiple metabolic receptors (GIP, GLP-1, and Glucagon) have demonstrated superior weight loss and glucose control compared to older GLP-1-only medications. This suggests that targeting multiple hormonal pathways simultaneously may offer better clinical outcomes than single-pathway treatments.

Higher BMI causally increases the risk of coronary heart disease (CHD), and this effect is significantly mediated by elevated triacylglycerol levels, higher HbA1c, and type 2 diabetes risk.

High body weight increases heart disease risk, but much of that risk comes from how it affects your blood fats (triglycerides) and blood sugar (HbA1c/Diabetes). Managing these specific metabolic markers is crucial for heart health, potentially more so than focusing on LDL cholesterol alone, which this study suggests isn't a primary mediator of BMI's effect.

Bariatric surgery reverses obesity-associated secondary hypogonadism (MOSH) in men, leading to increased total and free testosterone levels and improved sexual function.

If you are a severely obese man with low testosterone, bariatric surgery can naturally restore your hormone levels and sexual function by reversing the obesity that was suppressing your hormones.

Evening exercise training (18:30 hours) improves glycaemic control and reverses high-fat diet-induced metabolic perturbations in overweight/obese men, whereas morning exercise (06:30 hours) does not.

If your goal is optimizing blood sugar control and metabolic health, especially if you consume a high-fat diet, try to schedule your workouts for the evening (around 18:30). Morning exercise still improves your heart and lung fitness, but it may not offer the same metabolic protection against poor diet choices. If you must exercise in the morning, be mindful that it might not counteract the negative metabolic effects of a high-fat diet as effectively as evening training.

Oral semaglutide (7-14 mg/day) provides glucose-lowering and weight-loss effects comparable to subcutaneous formulations, though with lower bioavailability requiring higher doses.

If you prefer pills over injections, oral semaglutide is an option. You must take it on an empty stomach before breakfast, which requires discipline. It uses a higher dose than the shot version to compensate for lower absorption.

Vagal afferent signaling mediates nutrient-specific learning and satiation, and its blunting in obesity contributes to excessive weight gain, while targeted neuromodulation (stimulation or blockade) can reduce food intake and body weight.

Your gut communicates directly with your brain via the vagus nerve to regulate hunger and satiety. In obesity, this signal can become blunted. Therapies that stimulate this nerve (like non-invasive vagus nerve stimulation) or mimic gut hormones (like GLP-1 agonists) can help restore this signaling, reducing food intake and aiding weight loss. Focus on strategies that support gut-brain communication.

Tirzepatide's GIP receptor agonism directly enhances adipocyte glucose uptake and lipid clearance in the fed state by cooperating with insulin, contributing to reduced serum triglycerides without increasing adiposity.

Tirzepatide works partly by helping your fat cells clear sugar and fat from your blood more effectively when you eat, thanks to its GIP receptor activity. This helps lower blood fat levels without making you gain more body fat, complementing the weight loss driven by other mechanisms.

In the fasted state (low insulin), tirzepatide's GIP receptor agonism stimulates lipolysis (fat breakdown) to release stored energy, counter-regulating insulin's storage signal.

When you are not eating, tirzepatide helps your fat cells release stored fat for energy. This happens because the drug's GIP activity stimulates fat breakdown when insulin is low, ensuring your body can access energy stores during fasting periods.

Both combined exercise/weight loss and exercise alone reduce low-grade inflammation (CRP) in CAD patients, but only the combined intervention significantly reduces TNFα and suPAR.

While exercise alone reduces general inflammation (CRP), adding weight loss to the regimen further reduces specific inflammatory markers (TNFα, suPAR) associated with plaque instability.

Individual variability in hypertrophic response to resistance exercise is largely determined by endogenous variables such as basal satellite cell content, androgen receptor content, and gene expression profiles, rather than just exogenous training variables.

Accept that your genetic makeup (basal satellite cell count, androgen receptors) influences how much muscle you can build. While you cannot change your genetics, you can maximize your potential by optimizing the primary drivers: consistent resistance training and adequate protein intake. Do not blame your program for genetic ceilings.

Metformin (850mg twice daily) reduces the incidence of type 2 diabetes by 31% in adults with prediabetes compared to placebo, with effects persisting for up to 22 years.

If you have prediabetes and are over 60, have a BMI over 35, or had gestational diabetes, ask your doctor about Metformin. It is a proven, low-cost way to significantly lower your risk of developing full-blown diabetes, with benefits lasting for decades.

Thiazolidinediones (specifically Pioglitazone) reduce the incidence of type 2 diabetes in individuals with impaired glucose tolerance, but their use is limited by adverse effects such as weight gain, fluid retention, and increased fracture risk.

Pioglitazone can prevent diabetes, but it often causes weight gain and other side effects. It is usually not the first choice; Metformin or GLP-1 medications are typically preferred unless Pioglitazone is specifically indicated for your case.

GLP-1/glucagon co-agonists achieve superior weight loss and metabolic improvements compared to GLP-1 mono-agonists by combining central appetite suppression with glucagon-mediated increases in energy expenditure and hepatic lipid oxidation.

GLP-1/glucagon co-agonists (like cotadutide and efinopegdutide) are emerging treatments that target both appetite and energy expenditure. They appear to offer greater weight loss than current GLP-1-only drugs (like semaglutide or liraglutide) and may also improve liver health. However, they carry a higher risk of gastrointestinal side effects like nausea and vomiting. Patients should expect a careful dose-titration process to manage these effects.

Skeletal muscle-derived VEGF, induced by endurance exercise via PGC-1α, mediates training-induced capillarization, enhancing oxygen and substrate delivery to muscle tissue.

Endurance training triggers your muscles to release VEGF locally, which builds new capillaries to improve oxygen delivery. You don't need to monitor blood VEGF levels to know this is happening; it is a standard, autonomous response to the stress of endurance exercise. Consistent training volume is the key driver.

Exenatide once weekly improves glycemic control (A1C and FPG) and cardiovascular risk markers (SBP, LDL-C, triglycerides) independently of weight loss, although the magnitude of improvement is greater in patients with higher weight loss.

If you have Type 2 Diabetes, Exenatide once weekly will lower your blood sugar (A1C) and improve heart health markers even if you don't lose weight. However, you will get the biggest benefits if you do lose weight. Be aware that those who lose the most weight are more likely to experience nausea or hypoglycemia, especially if you are also taking sulfonylureas. Most people tolerate the injection well.

Tirzepatide improves liver fat content and shows potential efficacy in treating nonalcoholic steatohepatitis (NASH) in patients with type 2 diabetes.

For patients with type 2 diabetes and fatty liver, tirzepatide significantly reduces liver fat content more than insulin therapy, potentially helping manage NASH.

Semaglutide significantly reduces high-sensitivity C-reactive protein (hsCRP) levels in patients with type 2 diabetes compared to placebo and active comparators, indicating an anti-inflammatory effect.

If you have type 2 diabetes, semaglutide (whether injected weekly or taken as a daily pill) significantly lowers hsCRP, a key marker of inflammation linked to heart disease risk. This reduction is greater than with placebo or other common diabetes drugs like exenatide or empagliflozin. While part of this benefit comes from losing weight and lowering blood sugar, there appears to be a direct anti-inflammatory effect. For patients with chronic kidney disease, the trend is positive but not statistically significant compared to placebo in this specific analysis, so discuss risks/benefits with your doctor.

Following 16 weeks of resistance training, the acute activation of muscle satellite cells (SC) in response to a single bout of exercise is augmented (increased Pax7+/MyoD+ cells and MyoD mRNA expression at 24h), which is accompanied by increased muscle fiber capillarization.

If you have been resistance training consistently for a few months, your muscles become more efficient at repairing themselves after a workout. Specifically, your muscle stem cells activate faster (within 24 hours) and express more growth-related genes (MyoD) after a single intense session compared to when you were a beginner. This suggests that long-term training enhances the muscle's ability to adapt to acute stress, likely supported by improved blood flow (capillarization) in the muscle.

In patients with new-onset type 2 diabetes, a weight gain of 10% or more within the first two years is associated with an increased risk of stroke.

If you have recently been diagnosed with type 2 diabetes, try to avoid gaining more than 10% of your body weight in the first two years. Significant weight gain is linked to a higher risk of stroke. Maintaining a stable weight is associated with the lowest risk of cardiovascular events and mortality.